Can We Improve Confusion, Uremia, Respiratory Rate, Blood Pressure, Age >65 with Lactate and Procalcitonin to Predict Mortality in Pneumonia?

Introduction: Pneumonia is a common diagnosis in the emergency department (ED). Some scoring systems such as Confusion, Uremia, Respiratory Rate, Blood Pressure, Age>65 (CURB-65) are used to determine the severity of this disease. We aimed to determine the best scoring system (CURB-65, serum lactate+CURB-65, serum procalcinonin+CURB-65) to predict the severity and 30-day mortality of pneumonia patients admitted to our ED. Methods: This study was planned as a prospective study. 480 community-acquired pneumonia patients admitted to our ED between February 1, 2020, and January 31, 2021, were included. CURB-65 score, CURB-65+lactate levels, and CURB65+procalcitonin levels were evaluated to predict disease severity. Results: A total of 480 pneumonia patients, 281 (58.5%) men and 199 (41.5%) women, with a mean age of 61.7 ± 19.06 years, were included in the study. The sensitivity/specificity pair and cut-off value of CURB-65 for 30-day mortality was 71.9/74.8%. These values were 68.5% and 61.9% for CURB-65+lactate (cut-off = 17.50) and 78.1% and 90.7% for CURB-65+procalcitonin (cut-off = 2.095). Discussion: Infectious diseases such as pneumonia, urinary tract infection, and sepsis are common reasons for ED presentations and may be fatal, especially in the elderly population. In such infectious diseases, it is difficult to predict the prognosis of the patients including discharge, hospitalization service, mortality probability in the EDs those are becoming much more crowded each day and several scoring systems have been improved. In this study, the highest sensitivity and specificity were determined in CURB-65+procalcitonin. Conclusion: CURB-65 is superior to CURB-65+lactate; however, CURB-65+procalcitonin is superior to both in predicting 30-day mortality

Synthesis of some heterocyclic phosphonates and their antibacterial and antifungal activities

197-200Fifteen heterocyclic phosphonate derivatives and their starting compounds have been evaluated in vitro for antibacterial and antifungal activities against standard strains: Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 2921)), Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853) and yeast-like fungi ; Candida albicans and <span style="font-size:16.0pt; mso-bidi-font-size:10.0pt;font-family:" times="" new="" roman";mso-fareast-font-family:="" "times="" roman";mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa"="">Candida tropicalis. <span style="font-size: 15.0pt;mso-bidi-font-size:9.0pt;font-family:" times="" new="" roman";mso-fareast-font-family:="" "times="" roman";mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa"="">The compounds newly synthesised have been identified by 1H-NMR,FT-IR and micro analysis. Among the tested compounds 12, 13, 16, 17, 18, 22 and 23 are found effective to inhibit the growth of <span style="font-size:16.0pt;mso-bidi-font-size:10.0pt; font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">Candida albicans <span style="font-size:15.0pt;mso-bidi-font-size:9.0pt; font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">and <span style="font-size:16.0pt;mso-bidi-font-size:10.0pt;font-family: " times="" new="" roman";mso-fareast-font-family:"times="" roman";mso-ansi-language:="" en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">Candida tropicalis at the MICs between <span style="font-size:14.5pt;mso-bidi-font-size:8.5pt;font-family:Arial;mso-fareast-font-family: " times="" new="" roman";mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa;mso-bidi-font-style:italic"="">100-800 μg/mL. The compounds tested here generally do not exhibit considerable antibacterial activity at the concentration studied (100-800 <span style="font-size:14.5pt;mso-bidi-font-size:8.5pt; font-family:Arial;mso-fareast-font-family:" times="" new="" roman";mso-ansi-language:="" en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa;mso-bidi-font-style:="" italic"="">μg/mL), <span style="font-size:15.0pt;mso-bidi-font-size: 9.0pt;font-family:" times="" new="" roman";mso-fareast-font-family:"times="" roman";="" mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa"="">except compound 18 which exhibits antibacterial activity against gram-positive bacteria at the MIC of 400 <span style="font-size:14.5pt;mso-bidi-font-size:8.5pt;font-family:Arial;mso-fareast-font-family: " times="" new="" roman";mso-ansi-language:en-us;mso-fareast-language:en-us;="" mso-bidi-language:ar-sa;mso-bidi-font-style:italic"="">μg/mL.</span

Epidemiological, Clinical, and Laboratory Features of Children With COVID-19 in Turkey

Objectives: The aim of this study is to identify the epidemiological, clinical, and laboratory features of coronavirus disease 2019 (COVID-19) in children